Table 2 Meta analyses of AIT in ashtma
Author, Year (REF) | Type of AIT | Studies | PATS (A/P)a | Results (effect size, 95 % C.I.) |
|---|---|---|---|---|
Abramson, 2010 [42] | SCIT | 34 symptoms | 727/557 | Symptoms −0.6 (−0.83 -0.35) significant |
20 medications | 485/384 | Medications −0.5 (−08 -0.3) significant | ||
Erekoshima 2013 [43] | SCIT | 10 symptoms | 320/308 | Strength of evidence reported as “high” for both outcomes |
8 medications | 285/288 | |||
Calamita, 2007 [44] | SLIT | 9 symptoms | 150/153 | Symptoms −0.38 (−0.79 0.03) not significant |
6 medications | 132/122 | Medications −0.9 (−1.9 -0.12) significant | ||
Penagos, 2008 [45] | SLITab | 9 symptoms | 232/209 | Symptoms −1.18 (−2.1 -018) significant |
7 medications | 192/174 | Medication −1.63 (−2.8 -044) significant | ||
Compalati, 2009 [46] | SLIT mite | 9 symptoms | 243/209 | Symptoms SMD 0.95 (1.74 0.15) significantabc |
7 medications | 102/100 | Medications SMD 1.48 (2.70 0.26) significant |